Header Logo

Connection

Heather Feigelson to Breast Neoplasms

Back to Details
This is a "connection" page, showing publications Heather Feigelson has written about Breast Neoplasms.
Heather Feigelson
Connection Strength
7.202
Breast Neoplasms
  1. Response to Comment on "Bariatric Surgery is Associated With Reduced Risk of Breast Cancer in Both Premenopausal and Postmenopausal Women". Ann Surg. 2020 02; 271(2):e19-e20.
    View in: PubMed
    Score: 0.394
  2. Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota. Br J Cancer. 2018 02 20; 118(4):471-479.
    View in: PubMed
    Score: 0.343
  3. Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study. J Natl Cancer Inst. 2015 Aug; 107(8).
    View in: PubMed
    Score: 0.285
  4. Reply: To PMID 23490543. J Am Coll Surg. 2013 Nov; 217(5):960-2.
    View in: PubMed
    Score: 0.256
  5. Factors associated with the frequency of initial total mastectomy: results of a multi-institutional study. J Am Coll Surg. 2013 May; 216(5):966-75.
    View in: PubMed
    Score: 0.244
  6. Weight loss and postmenopausal breast cancer in a prospective cohort of overweight and obese US women. Cancer Causes Control. 2011 Apr; 22(4):573-9.
    View in: PubMed
    Score: 0.212
  7. Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. Hum Mol Genet. 2010 Oct 01; 19(19):3873-84.
    View in: PubMed
    Score: 0.203
  8. No association between polymorphisms in LEP, LEPR, ADIPOQ, ADIPOR1, or ADIPOR2 and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2009 Sep; 18(9):2553-7.
    View in: PubMed
    Score: 0.191
  9. Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II. Breast Cancer Res. 2008; 10(4):R57.
    View in: PubMed
    Score: 0.177
  10. Adult weight gain and histopathologic characteristics of breast cancer among postmenopausal women. Cancer. 2006 Jul 01; 107(1):12-21.
    View in: PubMed
    Score: 0.154
  11. Transforming growth factor beta receptor type I and transforming growth factor beta1 polymorphisms are not associated with postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2006 Jun; 15(6):1236-7.
    View in: PubMed
    Score: 0.153
  12. Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies. Cancer Res. 2006 Feb 15; 66(4):2468-75.
    View in: PubMed
    Score: 0.150
  13. Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001 to 2018. Breast Cancer Res Treat. 2024 Dec; 208(3):577-587.
    View in: PubMed
    Score: 0.135
  14. Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in US breast cancer survivors. J Natl Cancer Inst. 2024 Aug 01; 116(8):1384-1394.
    View in: PubMed
    Score: 0.135
  15. No association between the progesterone receptor gene +331G/A polymorphism and breast cancer. Cancer Epidemiol Biomarkers Prev. 2004 Jun; 13(6):1084-5.
    View in: PubMed
    Score: 0.133
  16. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev. 2004 Feb; 13(2):220-4.
    View in: PubMed
    Score: 0.130
  17. Utilization of neoadjuvant chemotherapy varies in the treatment of women with invasive breast cancer. PLoS One. 2013; 8(12):e84535.
    View in: PubMed
    Score: 0.129
  18. Longitudinal adherence to breast cancer surveillance following cancer genetic testing in an integrated health care system. Breast Cancer Res Treat. 2023 Oct; 201(3):461-470.
    View in: PubMed
    Score: 0.125
  19. Risk of second primary cancer among women in the Kaiser Permanente Breast Cancer Survivors Cohort. Breast Cancer Res. 2023 05 03; 25(1):50.
    View in: PubMed
    Score: 0.123
  20. Alcohol, folate, methionine, and risk of incident breast cancer in the American Cancer Society Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2003 Feb; 12(2):161-4.
    View in: PubMed
    Score: 0.121
  21. Treatment-related thoracic soft tissue sarcomas in US breast cancer survivors: a retrospective cohort study. Lancet Oncol. 2022 11; 23(11):1451-1464.
    View in: PubMed
    Score: 0.119
  22. Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis. 2002 Sep; 17(5):445-6; author reply 447-8.
    View in: PubMed
    Score: 0.118
  23. Risk-reducing surgery in unaffected individuals receiving cancer genetic testing in an integrated health care system. Cancer. 2022 Aug 15; 128(16):3090-3098.
    View in: PubMed
    Score: 0.116
  24. The influence of treatment on hormone receptor subgroups and breast cancer-specific mortality within US integrated healthcare systems. Cancer Causes Control. 2022 Jul; 33(7):1019-1023.
    View in: PubMed
    Score: 0.115
  25. Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016. Breast Cancer Res Treat. 2022 May; 193(1):203-216.
    View in: PubMed
    Score: 0.114
  26. Alcohol consumption increases the risk of fatal breast cancer (United States). Cancer Causes Control. 2001 Dec; 12(10):895-902.
    View in: PubMed
    Score: 0.112
  27. Molecular markers of risk of subsequent invasive breast cancer in women with ductal carcinoma in situ: protocol for a population-based cohort study. BMJ Open. 2021 10 26; 11(10):e053397.
    View in: PubMed
    Score: 0.111
  28. Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res. 2001 Jan 15; 61(2):785-9.
    View in: PubMed
    Score: 0.105
  29. Future possibilities in the prevention of breast cancer: role of genetic variation in breast cancer prevention. Breast Cancer Res. 2000; 2(4):277-82.
    View in: PubMed
    Score: 0.101
  30. Hormonal carcinogenesis. Carcinogenesis. 2000 Mar; 21(3):427-33.
    View in: PubMed
    Score: 0.099
  31. Cytochrome P450c17alpha gene (CYP17) polymorphism predicts use of hormone replacement therapy. Cancer Res. 1999 Aug 15; 59(16):3908-10.
    View in: PubMed
    Score: 0.095
  32. Sex steroid hormones and genetic susceptibility to breast and prostate cancer. Drug Metab Rev. 1998 May; 30(2):421-34.
    View in: PubMed
    Score: 0.087
  33. Re: Recent trends in U.S. breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst. 1997 Dec 03; 89(23):1810-2.
    View in: PubMed
    Score: 0.085
  34. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res. 1997 Mar 15; 57(6):1063-5.
    View in: PubMed
    Score: 0.081
  35. Risk of Breast Cancer With Long-Term Use of Calcium Channel Blockers or Angiotensin-Converting Enzyme Inhibitors Among Older Women. Am J Epidemiol. 2017 02 15; 185(4):264-273.
    View in: PubMed
    Score: 0.080
  36. Estrogens and breast cancer. Carcinogenesis. 1996 Nov; 17(11):2279-84.
    View in: PubMed
    Score: 0.079
  37. Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting. JAMA Oncol. 2017 02 09; 3(2):186-193.
    View in: PubMed
    Score: 0.078
  38. Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium. Breast Cancer Res Treat. 2016 Feb; 155(3):531-40.
    View in: PubMed
    Score: 0.075
  39. Genetic susceptibility to cancer from exogenous and endogenous exposures. J Cell Biochem Suppl. 1996; 25:15-22.
    View in: PubMed
    Score: 0.074
  40. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet. 2013 Apr; 45(4):392-8, 398e1-2.
    View in: PubMed
    Score: 0.061
  41. Utilization of HER2 genetic testing in a multi-institutional observational study. Am J Manag Care. 2012 Nov; 18(11):704-12.
    View in: PubMed
    Score: 0.060
  42. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet. 2012 Dec 15; 21(24):5373-84.
    View in: PubMed
    Score: 0.059
  43. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012 Sep 05; 104(17):1293-305.
    View in: PubMed
    Score: 0.059
  44. Improving quality of breast cancer surgery through development of a national breast cancer surgical outcomes (BRCASO) research database. BMC Cancer. 2012 Apr 03; 12:136.
    View in: PubMed
    Score: 0.057
  45. Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure. Cancer Epidemiol Biomarkers Prev. 2012 Apr; 21(4):673-80.
    View in: PubMed
    Score: 0.057
  46. Variability in reexcision following breast conservation surgery. JAMA. 2012 Feb 01; 307(5):467-75.
    View in: PubMed
    Score: 0.057
  47. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet. 2011 Oct 30; 43(12):1210-4.
    View in: PubMed
    Score: 0.056
  48. Fine mapping of 14q24.1 breast cancer susceptibility locus. Hum Genet. 2012 Mar; 131(3):479-90.
    View in: PubMed
    Score: 0.055
  49. Comprehensive analysis of hormone and genetic variation in 36 genes related to steroid hormone metabolism in pre- and postmenopausal women from the breast and prostate cancer cohort consortium (BPC3). J Clin Endocrinol Metab. 2011 Feb; 96(2):E360-7.
    View in: PubMed
    Score: 0.052
  50. Performance of common genetic variants in breast-cancer risk models. N Engl J Med. 2010 Mar 18; 362(11):986-93.
    View in: PubMed
    Score: 0.050
  51. PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis. 2010 Mar; 31(3):455-61.
    View in: PubMed
    Score: 0.049
  52. Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). BMC Cancer. 2009 Jul 29; 9:257.
    View in: PubMed
    Score: 0.048
  53. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet. 2009 May; 41(5):585-90.
    View in: PubMed
    Score: 0.046
  54. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet. 2009 May; 41(5):579-84.
    View in: PubMed
    Score: 0.046
  55. Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype. Cancer. 2009 Mar 01; 115(5):936-45.
    View in: PubMed
    Score: 0.046
  56. Vitamin D receptor polymorphisms and breast cancer risk: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2009 Jan; 18(1):297-305.
    View in: PubMed
    Score: 0.046
  57. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS One. 2008 Jul 02; 3(7):e2578.
    View in: PubMed
    Score: 0.044
  58. Haplotypes of the estrogen receptor beta gene and breast cancer risk. Int J Cancer. 2008 Jan 15; 122(2):387-92.
    View in: PubMed
    Score: 0.043
  59. Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2007 Oct; 16(10):1973-81.
    View in: PubMed
    Score: 0.042
  60. Association of polymorphisms in one-carbon metabolism genes and postmenopausal breast cancer incidence. Cancer Epidemiol Biomarkers Prev. 2007 Jun; 16(6):1140-7.
    View in: PubMed
    Score: 0.041
  61. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007 Jul; 39(7):870-4.
    View in: PubMed
    Score: 0.041
  62. A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res. 2007 Apr 01; 67(7):2951-6.
    View in: PubMed
    Score: 0.040
  63. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res. 2007 Mar 01; 67(5):1893-7.
    View in: PubMed
    Score: 0.040
  64. Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Res. 2007; 9(1):R9.
    View in: PubMed
    Score: 0.040
  65. Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res. 2006; 8(2):R22.
    View in: PubMed
    Score: 0.038
  66. A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Breast Cancer Res. 2006; 8(5):R54.
    View in: PubMed
    Score: 0.037
  67. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer. 2005 12; 5(12):977-85.
    View in: PubMed
    Score: 0.037
  68. Dairy, calcium, and vitamin D intake and postmenopausal breast cancer risk in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2005 Dec; 14(12):2898-904.
    View in: PubMed
    Score: 0.037
  69. A prospective study of XRCC1 (X-ray cross-complementing group 1) polymorphisms and breast cancer risk. Breast Cancer Res. 2005; 7(6):R1168-73.
    View in: PubMed
    Score: 0.037
  70. Risk factors for fatal breast cancer in African-American women and White women in a large US prospective cohort. Am J Epidemiol. 2005 Oct 15; 162(8):734-42.
    View in: PubMed
    Score: 0.036
  71. Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev. 2005 Jan; 14(1):261-4.
    View in: PubMed
    Score: 0.035
  72. Breast cancer in a multiethnic cohort in Hawaii and Los Angeles: risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in whites. Cancer Epidemiol Biomarkers Prev. 2002 Sep; 11(9):795-800.
    View in: PubMed
    Score: 0.029
  73. T1 breast carcinoma in women 70 years of age and older may not require axillary lymph node dissection. Am J Surg. 1996 Nov; 172(5):487-9; discussion 489-90.
    View in: PubMed
    Score: 0.020
  74. A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. J Clin Endocrinol Metab. 2010 Sep; 95(9):E121-7.
    View in: PubMed
    Score: 0.013
  75. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet. 2010 Aug 01; 19(15):3089-101.
    View in: PubMed
    Score: 0.013

© 2024 Kaiser Permanente